Malignancy marker for therapy planning
Blood based test for an early classification of aggressive prostate cancers for personalized therapy planning.
Early classification of aggressive prostate cancers for personalized therapy planning.
Applicable for analyzing tissue samples and liquid biopsies.
Also relevant for other tumor entities (e.g. esophagus, breast cancer).
Additional biomarker that can be measured in an easy and objective way.
Prostate cancer diagnosis and classification, Therapeutic strategies
Vimentin 3 (Vim3) has been discovered as
biomarker, which correlates with the risk of
progression of prostate cancer. Results
show high expression of Vim3 in cells of
metastatic prostate and low expression in
non-metastatic cancer, thus demonstrating
the potential of Vim3 for risk stratification of
localized prostate carcioma to enable personalized therapy planning
Licensing
02/10/2018 00:00:00
WO2018EP58923 20180406
- international:
G01N33/50
- cooperative:
G01N33/5091; G01N2800/367
Patent application
5158
德國
